Nsc745885
Modify Date: 2025-09-25 17:06:50
Nsc745885 structure
|
Common Name | Nsc745885 | ||
|---|---|---|---|---|
| CAS Number | 4219-52-7 | Molecular Weight | 266.27 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C14H6N2O2S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Nsc745885NSC745885 an effective anti-tumor agent, shows selective toxicity against multiple cancer cell lines but not normal cells. NSC745885 is an effective down-regulator of EZH2 via proteasome-mediated degradation. NSC745885 provides possibilities for the study of advanced bladder and oral squamous cell carcinoma (OSCC) cancers[1][2]. |
| Name | NSC745885 |
|---|
| Description | NSC745885 an effective anti-tumor agent, shows selective toxicity against multiple cancer cell lines but not normal cells. NSC745885 is an effective down-regulator of EZH2 via proteasome-mediated degradation. NSC745885 provides possibilities for the study of advanced bladder and oral squamous cell carcinoma (OSCC) cancers[1][2]. |
|---|---|
| Related Catalog | |
| Target |
EZH2 |
| In Vitro | NSC745885 (0.5-4 μM; 24, 48 or 72 hours) has a growth inhibitory or death-promoting effect on the SAS cells, it significantly decreases the densities of cultured cells when compared with untreated cells. The IC50 of NSC745885 is 0.85 μM after 72 hours’ treatment[1]. NSC745885 (0.5-4 μM; 24 hours) increases annexin V positive cells in a dose-dependent manner, and the differences appears as a dose-dependent manner[1]. NSC745885 (0.5-2 μM; 24 or 48 hours) decreases XIAP protein levels and increases protein levels both as a dose-dependent manner in SAS cells[1]. Cell Viability Assay[1] Cell Line: SAS cells is obtained from a poorly differentiated human squamous cell carcinoma Concentration: 0.5 μM, 1 μM, 1.5 μM, 2 μM, 4 μM Incubation Time: 24, 48, or 72 hours Result: Decreases SAS cells growth as a time and dose-dependent manner. Apoptosis Analysis[1] Cell Line: SAS cells is obtained from a poorly differentiated human squamous cell carcinoma Concentration: 0.5 μM, 1 μM, 1.5 μM, 2 μM, 4 μM Incubation Time: 24 hours Result: Decreases SAS cells growth as a time and dose-dependent manner. Western Blot Analysis[1] Cell Line: SAS cells is obtained from a poorly differentiated human squamous cell carcinoma Concentration: 0.5 μM, 1 μM, 1.5 μM, 2 μM Incubation Time: 24 or 48 hours Result: Increased cleaved caspase-3 expression and decreased XIAP expression. |
| In Vivo | NSC745885 (intraperitoneal injection; 2 mg/kg; once daily; 10 days) treatment significantly reduces tumor size when compared with the vehicle control, and exhibits a higher safety than doxorubicin[1]. Animal Model: Eight-week-old NOD/SCID (NOD.CB17 Prkdcscid/J) mice[1] Dosage: 2 mg/kg Administration: Intraperitoneal injection; 2 mg/kg; once daily; 10 days Result: Inhibited engrafted tumors growth in vivo. |
| References |
| Molecular Formula | C14H6N2O2S |
|---|---|
| Molecular Weight | 266.27 |
| InChIKey | SJPXIVLTCBBWKT-UHFFFAOYSA-N |
| SMILES | O=C1c2ccccc2C(=O)c2c1ccc1nsnc21 |